MedPath

Minimization of maintenance immunosuppression early after renal transplantation.

Suspended
Conditions
renal transplantation, renal failureciclosporin, allograft nephropathy, everolimus, mycophenolate mofetyl.Niertransplantatie, ciclosporine, cardiovasculaire bijwerkingen
Registration Number
NL-OMON22724
Lead Sponsor
ovartis Pharma
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
Not specified
Target Recruitment
270
Inclusion Criteria

1. Patients, between the age of 18 en 70 years, receiving a first or second renal transplant;

2. Patients had to understand the purpose and risks of the study;

Exclusion Criteria

1. Patients with a HLA-identical sibling donor;

2. a third or a fourth transplant;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The degree of inflammation and fibrosis and the degree of arteriolar hyalinosis in renal biopsies taken at 6 and 24 months after implantation. Biopsies will be evaluated according to the Banff ‘97 Criteria for Renal Allograft Biopsy Interpretation (appendix II). Quantitative morphometric analysis of interstitial fibrous tissue will be performed using the digital image analysis technique
Secondary Outcome Measures
NameTimeMethod
1. Cardiovascular (surrogate) endpoints; IMT Intima/Media Thickness of the a. carotis interna;<br /><br>2. Blood pressure and the number of antihypertensives;<br /><br>3. Lipid profile;<br /><br>4. Renal allograft survival and function (Nankivell), and patient survival;<br /><br>5. The incidence of malignancies;<br /><br>6. Infectious complications;<br /><br>7. Miscellaneous;<br /> <br>fasting glucose, HbA1c, uric acid<br>MPA-levels and IMPDH activity over time, everolimus levels. MPA and everolimus levels over time (AUCs) will be correlated to graft function, rejection episodes and trough levels.<br>
© Copyright 2025. All Rights Reserved by MedPath